Search
Briacell Therapeutics Corp
BCTXAdd to Watchlist
3.470USD
+0.230+7.10%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
28.44MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01No earnings forecast score is currently available for Briacell Therapeutics Corp. The Biotechnology & Medical Research industry's average is 8.13. The average price target is 40.00, with a high of 40.00 and a low of 40.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
40.000
Target Price
+199.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Briacell Therapeutics Corp
BCTX
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Briacell Therapeutics Corp's expected revenue for the next quarter?
Briacell Therapeutics Corp's expected revenue is 2.10M.
What is Briacell Therapeutics Corp's price target?
Analysts forecast that Briacell Therapeutics Corp's price target is USD 40.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 40.00.
How have Briacell Therapeutics CorpBCTX's recent earnings per share performed?
The market expectation was USD -0.99, while Briacell Therapeutics CorpBCTX's earnings per share (EPS) for the previous quarter was USD -2.58. EPS for the next quarter is expected at USD -2.09.
What is the analyst rating for Briacell Therapeutics Corp?
Based on the ratings of Briacell Therapeutics Corp's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.